Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
Cancer Invest
; 29(4): 325-37, 2011 May.
Article
em En
| MEDLINE
| ID: mdl-21469981
ABSTRACT
Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Neoplasias Pulmonares
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Cancer Invest
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Estados Unidos